Japan competition for Plavix looms as prasugrel stacks up in comparative trial
This article was originally published in Scrip
Executive Summary
New detailed Phase III results for prasugrel show that the Daiichi Sankyo oral antiplatelet agent reduced the risk of major non-fatal cardiovascular events by 23%, with no increase in clinically relevant bleeding, compared with clopidogrel in Japanese patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).